Why the study?
Do atrial natriuretic peptide agonists and C-type natriuretic peptide antagonists have potential as antipanic and anxiolytic medications?
Do atrial natriuretic peptide agonists and C-type natriuretic peptide antagonists have potential as antipanic and anxiolytic medications?
Natriuretic peptides modulate stress responses, highlighting ANP agonists and CNP antagonists as potential novel psychotherapeutic medications for panic disorder.
Answers are grounded in this paper and cite their sources.
ANP agonists and CNP antagonists merit clinical investigation in panic disorder; leaves open efficacy in prospective trials.
Natriuretic peptides differentially modulate endocrine and behavioral stress responses in preclinical and human studies. While atrial natriuretic peptide inhibits the hypothalamic-pituitary-adrenocortical axis, C-type natriuretic peptide exerts stimulatory activity. In rodents, atrial natriuretic peptide reduces anxiety, whereas C-type natriuretic peptide has anxiogenic effects (mediated via corticotropin-releasing hormone). Patients with panic disorder show lower basal ANP plasma levels but a more pronounced release during experimentally induced panic attacks compared with controls. This could explain the absent pituitary-adrenocortical activation during panic anxiety and its paroxysmal nature. Furthermore, the effects of the panicogen cholecystokinin-tetrapeptide are attenuated by ANP pretreatment in panic patients, while C-type natriuretic peptide demonstrates anxiogenic action in healthy humans. Atrial natriuretic peptide agonists and C-type natriuretic peptide antagonists may have potential as a new class of antipanic and anxiolytic psychotherapeutic medication.
No takes yet. Share an insight, caveat, or question.
Kellner et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: